TITLE

Deals roundup

PUB. DATE
May 2008
SOURCE
Medical Device Daily;5/2/2008, Vol. 12 Issue 86, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the acquisition of St. Clair Health subsidiary Sculptor Developmental Technologies by Hospira, a global specialty and medication delivery company. As part of the acquisition agreement, St. Clair Hospital will be a development and test site for Hospira medication management products.
ACCESSION #
47364293

 

Related Articles

  • Deals roundup.  // Medical Device Daily;5/2/2008, Vol. 12 Issue 86, p4 

    The article reports on the acquisition of St. Clair Health subsidiary Sculptor Developmental Technologies by Hospira, a global specialty and medication delivery company. As part of the acquisition agreement, St. Clair Hospital will be a development and test site for Hospira medication management...

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/1/2008, Vol. 19 Issue 85, p4 

    This section offers news briefs in the biotechnology industry in the U.S. Beckman Coulter Inc. has acquired rights to testing for the hepatitis C virus from Siemens Healthcare Diagnostics Inc. Hospira Inc. has acquired Sculptor Developmental Technologies. Illumina Inc. and Genpathway Inc. have...

  • Hospira Buy Gives Pfizer Expertise in Biosimilars.  // Chain Drug Review;2/16/2015, Vol. 37 Issue 4, p60 

    The article reports that pharmaceutical company Pfizer Inc. is to acquire Hospira Inc. for about 17 billion dollars.

  • Hospira to Pay $400M to Acquire Orchid's Pharma Unit.  // India -- West;1/1/2010, Vol. 35 Issue 6, pB2 

    The article reports that Lake Forrest, Illinois-based specialty pharmaceutical manufacturer Hospira Inc. has agreed in paying 400 million dollars in acquiring Orchid Chemicals & Pharmaceuticals Ltd.'s pharmaceuticals unit.

  • Hospira Buys Facilities From Orchid.  // Chain Drug Review;9/24/2012, Vol. 34 Issue 16, p112 

    The article reports on the acquisition of Hospira Inc. of the antibiotic manufacturing and research and development facilities in Aurangabad, India owned by Orchid Chemicals and Pharmaceuticals Ltd., an Indian drug company.

  • Aptuit, Inc.  // Applied Clinical Trials;Dec2005, Vol. 14 Issue 12, p86 

    The article provides information about the pharmaceutical company, Aptuit. The motive of the company is to engineer a better drug development process-delivering critical expertise, technologies, facilities, ideas, and services to our customers, in a seamless and globally integrated offering. The...

  • Reality not insanity. Miller, Jim // Pharmaceutical Technology Europe;Nov2009, Vol. 21 Issue 11, p16 

    The article discusses the initiatives taken by major global biopharmaceutical companies to deal with the issues of new product development. The author noted that drug companies have diversified their business portfolios through mergers, acquisitions and licensing deals. The author cited that...

  • M&A not the only solution. Huggett, Brady // Nature Biotechnology;May2008, Vol. 26 Issue 5, p485 

    This article reports that data from Recombinant Capital shows that value in drug development comes from alliances, not from mergers and acquisitions. The study examined biotechnology drugs, their approval, and partnerships related to their development. The article also provides a chart on the...

  • US Oncology Is Set to Be Acquired by Mckesson.  // Chain Drug Review;11/22/2010, Vol. 32 Issue 20, p55 

    The article offers updates related to health care services in the U.S. including the acquisition of US Oncology Inc. by McKesson Corp., the plan of the country's Food and Drug Administration (FDA) to develop methods that could assess new drug products and the revelation of New York eHealth...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics